Compare PRTA & SES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | SES |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.7M | 384.1M |
| IPO Year | 2013 | 2020 |
| Metric | PRTA | SES |
|---|---|---|
| Price | $9.03 | $0.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $19.00 | $4.00 |
| AVG Volume (30 Days) | 471.8K | ★ 18.2M |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.03 |
| EPS | ★ 0.26 | N/A |
| Revenue | $814,000.00 | ★ $21,000,000.00 |
| Revenue This Year | $1,111.38 | $53.90 |
| Revenue Next Year | N/A | $111.26 |
| P/E Ratio | $35.73 | ★ N/A |
| Revenue Growth | N/A | ★ 929.41 |
| 52 Week Low | $7.73 | $0.49 |
| 52 Week High | $11.80 | $3.73 |
| Indicator | PRTA | SES |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 37.49 |
| Support Level | $8.91 | $0.49 |
| Resistance Level | $9.36 | $0.67 |
| Average True Range (ATR) | 0.41 | 0.06 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 70.19 | 5.14 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
SES AI Corp is a developer and manufacturer of rechargeable battery technologies and battery materials for Energy Storage Systems (ESS), Urban Air Mobility (UAM), drones, robotics, electric vehicles (EVs), and other applications. For Enery Storage Systems, the company supplies hardware and software solutions with battery health and safety management software powered by its AI-based platform, Molecular Universe. Additionally, it offers battery materials and high-energy and power-density Li-Metal and Li-ion cells, which can be used for drones, UAM, robotics, and EV applications. The company also offers access to Molecular Universe as a software product. Currently, it generates maximum revenue from the development of Li-ion and Li-Metal battery materials as per the client's specifications.